Word abonnee en neem Beursduivel Premium
Rode planeet als pijlen grid met hoorntjes Beursduivel
Uitgebreid zoeken
Aandeel

Pharming Group NL0010391025

Laatste koers (eur)

0,904

  • Verschill

    +0,005 +0,61%

  • Volume

    3.074.267 Gem. (3M) 6,6M

  • Bied

    0,904  

  • Laat

    0,905  
+ Toevoegen aan watchlist

Pharming het aandeel van 2017

50.750 Posts
Pagina: «« 1 ... 1048 1049 1050 1051 1052 ... 2538 »» | Laatste | Omlaag ↓
  5. [verwijderd] 27 juli 2017 07:08

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Bericht dat veel te veel is opgemaakt in mijn opinie.

    Na ver zoeken:
    with net sales of $15.3 million in Q2 ($15.5 million in Q1) despite stock level adjustments.

    Vrij zwak, ik verwacht serieuze winstnemingen de komende dagen.
    Had er meer dan verwacht aangezien men duidelijk aangaf dat er een serieuze vraag is in de markt.
  6. [verwijderd] 27 juli 2017 07:09

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Pharming Reports on Financial Results for the First Half of 2017

    Record revenue from product sales up 617% on 2016 marks Pharming’s first half year of operational profitability

    Investment in commercial infrastructure to drive long-term sales growth

    Leiden, The Netherlands, 27 July 2017: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM) presents its (unaudited) financial report for the six months ended 30 June 2017.

    The Company will hold a conference call at 13:00 CEDT/ 07:00 EDT today: dial-in details can be found on page 7.

    Operational Highlights

    Accelerated the delivery of operating profitability as a result of strategic decision to reacquire commercial rights to RUCONEST® in North America
    Positive EMA amendment to the marketing authorization in Europe to allow self-administration of RUCONEST® for HAE attacks with a new custom-designed RUCONEST® Administration Kit
    Integration of the Ruconest North America business acquired from Valeant Pharmaceuticals International, inc. in December 2016 into Pharming is on track, with full transition of services from Valeant completed
    Completed investment in expanding US commercialization team
    Successfully refinanced company debt on more favourable commercial terms in order to recover dilutive share capital and release short and medium term cash to invest in accelerating commercialization
    Financial Highlights

    Revenues from product sales for the half year increased by 617% to €30.1 million (HY 2016: €4.2 million), as a result of the combined effect of receiving all of the revenue from US product sales (instead of the previous 30% supply share of net sales) and increasing patient numbers and product sales
    Total revenues increased by 477% to €30.6 million (including €0.5 million of license revenue) from €5.3 million (including €1.1 million in license revenue) in HY 2016
    Operating results improved to a profit of €4.2 million from a loss of €6.2 million in HY 2016, despite a considerable increase in commercialization activities, especially in the US
    The net result was a loss of €30.2 million (HY 2016: loss of €6.7 million), mainly as a result of non-cash financing expenses required to be shown under IFRS associated with the extinction of the Amortising Convertible Bonds 2017/2018 and replacement of the previous debt facility
    The company’s cash position decreased from €32.1 million at year-end 2016 to €25.2 million at 30 June 2017 (up from €21.7 million at 30 June 2016), largely due to late payments by debtors of revenues relating to US sales.
    Sijmen de Vries, CEO, said:

    “We are delighted with a second quarter of profitable operations, even after increased costs as we finish our integration and infrastructure investments. Now that our capital position is properly secured following the refinancing in May/July 2017, we can look forward to more stable growth as the big one-off accounting costs have been taken in this quarter.”

  8. jurpsy 27 juli 2017 07:10

    • jurpsy

      Lid sinds: 22 nov 2004

      Laatste bezoek: 03 mei 2024

    • Aanbevelingen

      Ontvangen: 1287

      Gegeven: 9262

    •    Aantal posts: 1.168

    Goedemorgen,

    Dat wordt 60 a 70 miljoen euro inkomsten op jaarbasis.
    Een jaar geleden stonden ze nog met de billen bloot.

    suc6.

    jurps

  9. [verwijderd] 27 juli 2017 07:11

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0


    Chief Executive Officer’s Comment

    Our strategic decision to re-acquire the commercial rights to sell RUCONEST® in North America has significantly increased revenue and profit generation for the first half of the year compared to the first half of 2016.

    Product sales for the half year increased by 617% to €30.1 million (HY 2016: €4.2 million). The positive sales momentum in the US continued in Q2, following higher than expected sales in Q1, with net sales of $15.3 million in Q2 ($15.5 million in Q1) despite stock level adjustments.

    Combined with ongoing growth in the number of US patients entering our full patient care plan, RUCONEST® SOLUTIONS, and new European patients starting RUCONEST® therapy with our recently introduced EU home use kit, we expect sales to increase in H2.

    Our strategy of increasing market access in the US with our sales, market access, nursing and patient management teams, and in the EU with continued expansion of our direct commercialization efforts, is driving the growth in new patients using RUCONEST®. As previously announced, marketing costs have increased as a direct result of hiring additional US personnel and start-up investments in marketing activities.

    Underlying sales volumes somewhat increased in Q2. On a reported basis, however, Q2 sales were slightly reduced to €14.9 million, from €15.2 million in Q1, reflecting the adverse movement in exchange rates (the dollar weakened against the euro). This was offset by a better performance in the EU and the Rest of the World (RoW) sales, which were up from €0.7 million in Q1 to €0.9 million in Q2.

    Gross profits reduced in line with the reduction in sales expressed in euros from €13.8 million in Q1 to €13.2 million in Q2, also reflecting slightly higher costs of goods and the higher mix of lower-margin RoW sales. We remain focused on increasing efficiency and controlling costs.

    Operating profit for the first half of the year was €4.2 million, of which €3.9 million was recorded in Q1. As previously guided, we have invested in expanding the US sales and marketing team and making further significant investments in our market presence especially in the USA, the costs of which are reflected in a lower operating profit for Q2. We expect to see the benefits of this investment in subsequent periods.

    In March, the European Commission adopted the Commission Implementing Decision to amend the marketing authorisation for RUCONEST® to include self-administration using the RUCONEST® Administration Kit. This decision allows for self-administration of RUCONEST® for acute hereditary angioedema (HAE) attacks by adolescents and adults with a new custom-designed RUCONEST® Administration Kit in the comfort and privacy of their own homes or at any other place they choose, without the necessity of a healthcare professional (HCP) being present. The Administration Kit is now available for use in various EU markets, following approval of the Educational Materials by the local authorities in those markets.

    In May, we announced a major refinancing of most of the financial instruments taken out in order to complete the acquisition of the commercialization rights to RUCONEST® from Valeant Pharmaceuticals International, Inc. (“Valeant”) (NYSE/TSX: VRX). Pharming completed a new US$100 million finance agreement with Orbimed Advisors. The new facility has been used to redeem the Amortizing Convertible Bonds due 2017/2018 and to refinance the Company’s senior debt facility with Silicon Valley Bank and Kreos Capital, together with the associated prepayment fees, legal fees and other costs of the transaction. The loan, initially structured as a bridge facility, was replaced last week by a full loan agreement with a maturity date of July 2021 under the same terms and conditions. This refinance enabled the company to recover 115 million shares, which had been set aside to meet conversions of the Amortizing Convertible Bonds, thereby removing the risk of 24% dilution from conversion of these Bonds from existing shareholders. At the same time, we were able to lower the cash cost of the debt overall and to reduce significantly the non-cash accounting effects of the Amortizing Bonds, which amounted to almost €8 million in Q1 2017 alone.

    As expected, net profit was impacted by the one-off legal, accounting and other professional services costs resulting from the refinancing in May, which amounted to €16.1 million before non-cash financing expenses required to be shown under IFRS associated with the extinction of the Amortising Convertible Bonds 2017/2018 and replacement of the old debt facility.

    Based on the increased momentum in sales volumes, underlying improving trends in identifying and diagnosing patients, combined with better patient care and management practices, and a focus on specialty pharmacy customers, we expect to further increase sales. We will continue to control costs and investments to improve profitability and drive sustainable long-term growth. We continue to expect additional positive operating results for the remainder of the year. No further financial guidance is provided.

    Sijmen de Vries

    Chief Executive Officer

    Click here to download the full press release

    print
    Share This Story, Choose Your Platform!

    FacebookTwitterLinkedinRedditTumblrGoogle+PinterestVkEmail
  10. [verwijderd] 27 juli 2017 07:12

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    VERSCHRIKKELIJK !!!!!!!!!!!!!!!!!!!!!!!!!!

    ZELFS IK MET MIJN ZWARTE BRIL HAD DIT OOK NIET VERWACHT !!!!!!

    sorry, maar dit gaat zware klappen opleveren.

    sta niet te kijken van 15 tot 20 cent vrije val. waardeloos.
  13. Renecs 27 juli 2017 07:14

    • Renecs

      Lid sinds: 19 jan 2017

      Laatste bezoek: 08 dec 2022

    • Aanbevelingen

      Ontvangen: 22

      Gegeven: 75

    •    Aantal posts: 118

    Goedemorgen, vrees dat veel mensen niet verder zullen lezen als:

    "Pharming nettoverlies eerste halfjaar 2017 30,2 miljoen euro, vs 6,7 miljoen verlies een jaar eerder"

    Maar als mensen verder kijken naar de cijfers, zien deze er volgens mij gewoon goed en veelbelovend uit naar mijn idee.
  14. [verwijderd] 27 juli 2017 07:14

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Ik denk dat het derde kwartaal al hogere cijfers gaat laten zien, misschien kunnen ze dit jaar al de 80 a 90 miljoen laten zien .
    En voor het volgend jaar voorzie ik een stijging ver boven de 100 miljoen.
    Met de cijfers van nu ben ik tevreden die men in die korte tijd hebben weten te maken, de omslag is gaande nu alleen nog de acceleratie
  15. jakhals 27 juli 2017 07:15

    • jakhals

      Lid sinds: 21 mrt 2014

      Laatste bezoek: 26 aug 2023

    • Aanbevelingen

      Ontvangen: 698

      Gegeven: 588

    •    Aantal posts: 2.619

    quote:

    Winstgevend schreef op 27 juli 2017 07:12:

    VERSCHRIKKELIJK !!!!!!!!!!!!!!!!!!!!!!!!!!

    ZELFS IK MET MIJN ZWARTE BRIL HAD DIT OOK NIET VERWACHT !!!!!!

    sorry, maar dit gaat zware klappen opleveren.

    sta niet te kijken van 15 tot 20 cent vrije val. waardeloos.
    Wegewezen dan
  16. [verwijderd] 27 juli 2017 07:15

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    SijmendeVries schreef op 27 juli 2017 07:12:

    Goedemorgen Pharming-volgers,

    Hierbij de link naar het Halfjaarbericht van Pharming dat we zonet gedistribueerd hebben.

    Met vriendelijke groet,

    Sijmen de Vries, CEO Pharming Group NV

    www.lifespring.nl/view_web_version?da...
    U kunt het ook niet helpen,

    Gecondoleerd met uw halfjaar cijfers.
  19. Smakkie 27 juli 2017 07:19

    • Smakkie

      Lid sinds: 16 jun 2017

      Laatste bezoek: 23 jul 2022

    • Aanbevelingen

      Ontvangen: 77

      Gegeven: 28

    •    Aantal posts: 1.020

    Cijfers zoals ik verwachte. Prima toekomst perspectief. Blijf lekker zitten, kom vanaf 33 cent dus helemaal goed. Nu verkopen zou wel heel erg dom zijn.
  20. [verwijderd] 27 juli 2017 07:19

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Kosten lijken me niet echt onder bedwang gehouden:
    Netto resulteert een verlies van € 30,2 miljoen

    Dan weet ik nog niet zo of we in Q3/Q4 winst zullen halen.
    Iemand een opinie hierover (waar staan duidelijk de kosten exclusief afbetaling boete en kosten warrants?)
50.750 Posts
Pagina: «« 1 ... 1048 1049 1050 1051 1052 ... 2538 »» | Laatste |Omhoog ↑

Laatste Nieuws

  1. Beursblik: tegenvallend banenrapport nog niet alarmerend
  2. Wall Street koerst af op hogere opening
  3. Amerikaanse banengroei veel minder sterk dan verwacht
  4. Zilver kan nieuwe stijging inzetten
  5. Bel20 stijgt in aanloop naar Amerikaans banenrapport
  6. Nieuw hoofdstuk overnamestrijd: Glencore overweegt bod op Anglo American
  7. Europese beurzen hoger rond middaguur
  8. Brusselse beurs bouwt openingswinsten verder uit
  9. Britse dienstensector groeit fractioneel harder dan gedacht
  10. Beursblik: Ontex komt beloftes na
  11. Beursblik: kwartaalcijfers GBL verrassen niet
  12. Must read: Sell in May?

Meest Gelezen Premium

  1. Premium Premium
    Advieswijziging ASML
  2. Premium Premium
    Iets langer geduld met Besi
  3. Premium Premium
    Vooruitblik: TikTok-verkoop, Magnificent Seven, en een correctie, of meer?
  4. Premium Premium
    Tijd om het aandeel Adyen op te vissen?
  5. Premium Premium
    Uitstekende cijfers Flow Traders
  6. Premium Premium
    Modelportefeuilles: dit aandeel koerst 40% hoger, maar er zit nog meer in het vat
  7. Premium Premium
    Resultaten Microsoft zijn wake-up call: AI zorgt voor extra groei

Beleggingsideeën van onze partners

Macro & Bedrijfsagenda

  1. 03 mei

    1. Chinese beurzen gesloten ivm Labor Day
    2. Aperam Q1-cijfers
    3. Bpost Q1-cijfers
    4. Credit Agricole Q1-cijfers
    5. Ontex -Q1-cijfers
    6. Brunel Q1-cijfers
    7. Heijmans €0,89 ex-dividend
    8. VS banengroei en werkloosheid april Banengroei: 243K. Werkloosheid: 3,8%. Uurlonen: +0,3% MoM volitaliteit verwacht
    9. VS inkoopmanagersindex diensten S&P april (def)
    10. VS Inkoopmanagersindex diensten ISM april (def)
de volitaliteit verwacht indicator betekend: Market moving event/hoge(re) volatiliteit verwacht
Naar de hele agenda